Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years
Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years
The objective of this study is to evaluate the efficacy and safety of recombinant human
 growth hormone (r-hGH) treatment in girls with Turner Syndrome under the age of 4 years.
 After 4 years of treatment, height in these girls will be compared with an historical control
 group of untreated girls with Turner Syndrome, matched for age and height at baseline.
Inclusion Criteria:

 -  Young girls with turner syndrome proved by karyotype

 -  Growth hormone secretion confirmed with ornithin stimulation test

 -  Normal glucidic metabolism confirmed by assessment of HbA1c

 -  None associated severe pathology which could have impact on growth (i.e. renal
 insufficiency, decompensated heart failure)

 -  No previous or associated treatment with anabolic or sexual steroids

 -  Known parental height

 Exclusion Criteria:

 -  Severe associated pathology with impact on growth

 -  Concomitant treatment with impact on growth

 -  Previous or associated treatment with anabolic steroids

 -  Associated growth hormone deficiency